Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan.
There is no previous report of fatal interstitial pneumonitis related to the administration of yttirum-90 ibritumomab tiuxetan. We report first case of fatal interstitial pneumonitis in a 35-year-old female patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. A pathological evaluation through a surgical lung biopsy demonstrated a "interstitial pneumonitis" pattern. Although high-dose methylprednisolone was administered, she died due to acute respiratory distress syndrome, secondary to radioimmunotherapy-induced interstitial pneumonitis. In this report, we discuss the etiology, diagnosis, and management of radioimmunotherapy-induced interstitial pneumonitis.
Kim
Moon Jin
MJ
Department of Internal Medicine, School of Medicine, Gyeongsang National University, Jinju, Republic of Korea.
Lee
Gyeong-Won
GW
Seo
Jong Woo
JW
Kim
Hyun-Jung
HJ
Lim
Sung-Nam
SN
Suh
Cheolwon
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008168:Lung / Q000473:pathology / Q000601:surgery; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000150:complications* / Q000000981:diagnostic imaging; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000000981:diagnostic imaging; D013902:Radiography, Thoracic; D012008:Recurrence
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan